Overall - Flu vacccines were safe

clipped from www.ecdc.europa.eu Vaccine Safety - Update of the EMA’s European Pharmacovigilance Report On the 5th May 2010, the European medicines Agency (EMA) published the 17th edition of its European Pharmacovigilance Report. This report summarises the adverse drug reactions reported after the use of the four centrally authorised 2009 influenza A(H1N1) pandemic vaccines - Arepanrix, Celvapan, Focetria and Pandemrix - and the antiviral Tamiflu. This edition notes that again the vast majority of the adverse reactions that had been reported as of 25 April 2010 are considered to be non-serious, thus, the benefit-risk balance of the centrally authorised pandemic vaccines and antivirals for the current 2009 influenza A(H1N1) pandemic continues to be positive.